This company listing is no longer active
MorphoSys Balance Sheet Health
Financial Health criteria checks 2/6
MorphoSys has a total shareholder equity of €-261.7M and total debt of €1.7B, which brings its debt-to-equity ratio to -658%. Its total assets and total liabilities are €1.8B and €2.1B respectively.
Key information
-658.0%
Debt to equity ratio
€1.72b
Debt
| Interest coverage ratio | n/a |
| Cash | €630.77m |
| Equity | -€261.67m |
| Total liabilities | €2.09b |
| Total assets | €1.83b |
Recent financial health updates
Recent updates
MorphoSys: Hold Rating Until The Novartis Deal Closes
May 01Novartis And MorphoSys Are A Perfect Match
Feb 06MorphoSys: Positive Pelabresib Data Finally Unlocking Upside
Jan 18MorphoSys updates Q2 & FY22 guidance below prior provided levels
Jul 26MorphoSys May Not Recover From Adventurous Constellation Buyout
May 04Sierra Oncology's Strong Data In Myelofibrosis Challenges MorphoSys And Incyte
Jan 28Incyte and MorphoSys presents new three-year data for blood cancer therapy
Jun 04MorphoSys reports Q1 results
May 05MorphoSys AG appoints Sangamo 's Sung Lee as new CFO
Jan 06MorphoSys AG (MOR) Investor Presentation - Slideshow
Dec 08MorphoSys AG 2020 Q3 - Results - Earnings Call Presentation
Nov 22MorphoSys reports Q3 results
Nov 11Financial Position Analysis
Short Term Liabilities: MOR has negative shareholder equity, which is a more serious situation than short term assets not covering short term liabilities.
Long Term Liabilities: MOR has negative shareholder equity, which is a more serious situation than short term assets not covering long term liabilities.
Debt to Equity History and Analysis
Debt Level: MOR has negative shareholder equity, which is a more serious situation than a high debt level.
Reducing Debt: MOR's has negative shareholder equity, so we do not need to check if its debt has reduced over time.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: MOR has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: MOR has sufficient cash runway for more than 3 years if free cash flow continues to reduce at historical rates of 35.7% each year
Discover healthy companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/08/05 22:34 |
| End of Day Share Price | 2024/08/05 00:00 |
| Earnings | 2024/03/31 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
MorphoSys AG is covered by 35 analysts. 8 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Olav Zilian | Baader Helvea Equity Research |
| Brian Balchin | Barclays |
| Rosie Turner | Barclays |